Web15 jun. 2024 · HORRAD trial From 2004–2014, men ( n = 432) with PSA > 20 ng/ml (median: 142 ng/ml) with bone metastases on bone scan were included. In contrast to … WebSan Francisco, CA USA (UroToday.com) Herein, we report on the first presentation of the HORRAD trial – the first multi-center randomized controlled trial looking at the role of treatment of the primary prostate cancer malignancy in the setting of metastatic disease – to date, no other trials have reported on this clinical disease space.
Importance of radiotherapy to the primary in metastatic hormone ...
WebRecentelijk zijn de resultaten van de Nederlandse HORRAD-studie gepubliceerd [4]. Tussen 2004 en 2014 zijn in totaal 432 patiënten geïncludeerd in 28 Nederlandse centra. De inclusiecriteria waren een histologisch bewezen adenocarcinoom van de prostaat, een PSA van meer dan 20 ng/ml en ossale metastasen op een botscan. Web1 mrt. 2024 · The HORRAD trial is a multicentre RCT recruiting 432 patients with prostate-specific antigen (PSA) >20 Outcome measurements and statistical analysis Results and limitations Median PSA level was 142 p = 0.4). No significant difference was found in overall survival (hazard ratio [HR]: 0.90; 95% CI: 0.70–1.14; p = 0.4). chccs nutrislice
Treating the primary in metastatic prostate cancer: where do
Web15 sep. 2016 · Hormonale behandeling is de therapie van eerste keuze bij patiënten met een gemetastaseerd prostaatcarcinoom. Hiervoor wordt bij voorkeur gekozen voor een … WebThe HORRAD trial showed a similar but nonsignificant trend towards RT (hazard ratio 0.68; 95% CI 0.42-1.10). As a result, the 2024 European Association of Urology and National Comprehensive Cancer Network guidelines now include RT to the prostate as an option in the setting of low-volume metastatic disease. Web8 apr. 2024 · This promising result from the HORRAD study was further brought to light in the much larger Systemic Therapy in Advancing and Metastatic Prostate cancer … custom smoker firebox